173 related articles for article (PubMed ID: 29112937)
1. A ligand-based comparative molecular field analysis (CoMFA) and homology model based molecular docking studies on 3', 4'-dihydroxyflavones as rat 5-lipoxygenase inhibitors: Design of new inhibitors.
Ahamed TKS; Muraleedharan K
Comput Biol Chem; 2017 Dec; 71():188-200. PubMed ID: 29112937
[TBL] [Abstract][Full Text] [Related]
2. Active site characterization and structure based 3D-QSAR studies on non-redox type 5-lipoxygenase inhibitors.
Ul-Haq Z; Khan N; Zafar SK; Moin ST
Eur J Pharm Sci; 2016 Jun; 88():26-36. PubMed ID: 27044904
[TBL] [Abstract][Full Text] [Related]
3. CoMFA and CoMSIA studies on 5-hydroxyindole-3-carboxylate derivatives as 5-lipoxygenase inhibitors: generation of homology model and docking studies.
Aparoy P; Suresh GK; Kumar Reddy K; Reddanna P
Bioorg Med Chem Lett; 2011 Jan; 21(1):456-62. PubMed ID: 21084193
[TBL] [Abstract][Full Text] [Related]
4. Essential structural profile of a dual functional inhibitor against cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX): molecular docking and 3D-QSAR analyses on DHDMBF analogues.
Zheng M; Zhang Z; Zhu W; Liu H; Luo X; Chen K; Jiang H
Bioorg Med Chem; 2006 May; 14(10):3428-37. PubMed ID: 16458008
[TBL] [Abstract][Full Text] [Related]
5. Exploring QSARs for 5-lipoxygenase (5-LO) inhibitory activity of 2-substituted 5-hydroxyindole-3-carboxylates by CoMFA and CoMSIA.
Zheng J; Xiao G; Guo J; Zheng Y; Gao H; Zhao S; Zhang K; Sun P
Chem Biol Drug Des; 2011 Aug; 78(2):314-21. PubMed ID: 21599857
[TBL] [Abstract][Full Text] [Related]
6. Towards the In-silico Design of New HSP90 Inhibitors: Molecular Docking and 3D-QSAR CoMFA Studies of Tetrahydropyrido [4, 3-d] Pyrimidine Derivatives as HSP90 Inhibitors.
Sepehri B; Ghavami R
Med Chem; 2018; 14(5):439-450. PubMed ID: 29564982
[TBL] [Abstract][Full Text] [Related]
7. Design of new CD38 inhibitors based on CoMFA modelling and molecular docking analysis of 4‑amino-8-quinoline carboxamides and 2,4-diamino-8-quinazoline carboxamides.
Sepehri B; Ghavami R
SAR QSAR Environ Res; 2019 Jan; 30(1):21-38. PubMed ID: 30489181
[TBL] [Abstract][Full Text] [Related]
8. Molecular docking and CoMFA studies of thiazoloquin(az)olin(on)es as CD38 inhibitors: determination of inhibitory mechanism, pharmacophore interactions, and design of new inhibitors.
Sepehri B; Ghavami R
J Biomol Struct Dyn; 2017 Jul; 35(9):1890-1898. PubMed ID: 27577102
[TBL] [Abstract][Full Text] [Related]
9. Molecular modeling-driven approach for identification of Janus kinase 1 inhibitors through 3D-QSAR, docking and molecular dynamics simulations.
Itteboina R; Ballu S; Sivan SK; Manga V
J Recept Signal Transduct Res; 2017 Oct; 37(5):453-469. PubMed ID: 28537140
[TBL] [Abstract][Full Text] [Related]
10. QSAR classification-based virtual screening followed by molecular docking studies for identification of potential inhibitors of 5-lipoxygenase.
Shameera Ahamed TK; Rajan VK; Sabira K; Muraleedharan K
Comput Biol Chem; 2018 Dec; 77():154-166. PubMed ID: 30321850
[TBL] [Abstract][Full Text] [Related]
11. Docking and 3D-QSAR (quantitative structure activity relationship) studies of flavones, the potent inhibitors of p-glycoprotein targeting the nucleotide binding domain.
Kothandan G; Gadhe CG; Madhavan T; Choi CH; Cho SJ
Eur J Med Chem; 2011 Sep; 46(9):4078-88. PubMed ID: 21723648
[TBL] [Abstract][Full Text] [Related]
12. QSAR analysis of thiolactone derivatives using HQSAR, CoMFA and CoMSIA.
Sainy J; Sharma R
SAR QSAR Environ Res; 2015; 26(10):873-92. PubMed ID: 26524489
[TBL] [Abstract][Full Text] [Related]
13. Ligand-based 3D QSAR analysis of reactivation potency of mono- and bis-pyridinium aldoximes toward VX-inhibited rat acetylcholinesterase.
Dolezal R; Korabecny J; Malinak D; Honegr J; Musilek K; Kuca K
J Mol Graph Model; 2015 Mar; 56():113-29. PubMed ID: 25588616
[TBL] [Abstract][Full Text] [Related]
14. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
Hou T; Zhu L; Chen L; Xu X
J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
[TBL] [Abstract][Full Text] [Related]
15. Quantitative structure-activity relationship of organosulphur compounds as soybean 15-lipoxygenase inhibitors using CoMFA and CoMSIA.
Caballero J; Fernández M; Coll D
Chem Biol Drug Des; 2010 Dec; 76(6):511-7. PubMed ID: 21040497
[TBL] [Abstract][Full Text] [Related]
16. 3D-QSAR Studies on Barbituric Acid Derivatives as Urease Inhibitors and the Effect of Charges on the Quality of a Model.
Ul-Haq Z; Ashraf S; Al-Majid AM; Barakat A
Int J Mol Sci; 2016 Apr; 17(5):. PubMed ID: 27144563
[TBL] [Abstract][Full Text] [Related]
17. 3D-QSAR comparative molecular field analysis on opioid receptor antagonists: pooling data from different studies.
Peng Y; Keenan SM; Zhang Q; Kholodovych V; Welsh WJ
J Med Chem; 2005 Mar; 48(5):1620-9. PubMed ID: 15743203
[TBL] [Abstract][Full Text] [Related]
18. A systematic quantitative approach to rational drug design and discovery of novel human carbonic anhydrase IX inhibitors.
Sethi KK; Verma SM
J Enzyme Inhib Med Chem; 2014 Aug; 29(4):571-81. PubMed ID: 24090419
[TBL] [Abstract][Full Text] [Related]
19. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
Bhongade BA; Gadad AK
J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
[TBL] [Abstract][Full Text] [Related]
20. 3D-QSAR and molecular docking study of LRRK2 kinase inhibitors by CoMFA and CoMSIA methods.
Pourbasheer E; Aalizadeh R
SAR QSAR Environ Res; 2016 May; 27(5):385-407. PubMed ID: 27228480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
